6 completed, 2 terminated. 8 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Terminated 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Secukinumab - Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | Completed | Novartis Pharmaceuticals | 65 | 2024-03-27 | 2026-04-01 |
| Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers Tocilizumab Prefilled Syringe - Rheumatoid Arthritis, Giant Cell Arteritis | Phase 1 | Completed | Syneos Health | 300 | 2021-05-31 | 2024-01-05 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Tocilizumab - Giant Cell Arteritis | Phase 1 | Completed | Hoffmann-La Roche | 24 | 2019-08-05 | 2021-12-22 |
| Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Nivolumab - Autoimmune Diseases, Non-small Cell Lung Cancer | Phase 1 | Terminated | Alliance Foundation Trials, LLC. | 7 | 2019-06-27 | 2023-02-15 |
| Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Tocilizumab, Glucocorticoids - Giant Cell Arteritis | Phase 1 / Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 18 | 2018-12-01 | 2021-06-22 |
| Ustekinumab for the Treatment of Giant Cell Arteritis Ustekinumab, Prednisone - Giant Cell Arteritis, Temporal Arteritis | Phase 1 / Phase 2 | Terminated | Massachusetts General Hospital | 13 | 2016-12-01 | 2020-06-12 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| MRI Superficial Temporal Artery MRI - Temporal Arteritis | Phase 1 | Completed | University Health Network, Toronto | 5 | 2003-04-01 | 2007-04-23 |
Giant Cell Arteritis (8) · Arthritis, Rheumatoid (2) · Polymyalgia Rheumatica (2) · Autoimmune Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Choroidal Effusions (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Inflammation (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Ophthalmia, Sympathetic (1) · Panuveitis (1) · Psoriasis (1) · Uveitis (1)
Autoimmune Diseases of the Nervous System (8) · Brain Diseases (8) · Cardiovascular Diseases (8) · Central Nervous System Diseases (8) · Cerebrovascular Disorders (8) · Immune System Diseases (8) · Nervous System Diseases (8) · Skin Diseases (8) · Skin Diseases, Vascular (8) · Skin and Connective Tissue Diseases (8) · Vascular Diseases (8) · Vasculitis (8) · Vasculitis, Central Nervous System (8) · Autoimmune Diseases (7)
tocilizumab (3) · Adrenal Cortex Hormones (1) · Glucocorticoids (1) · Nivolumab (1) · Prednisone (1) · Triamcinolone (1) · Triamcinolone Acetonide (1) · Ustekinumab (1) · secukinumab (1)
Alliance Foundation Trials, LLC. (1) · Clearside Biomedical, Inc. (1) · Hoffmann-La Roche (1) · Insel Gruppe AG, University Hospital Bern (1) · Massachusetts General Hospital (1) · Novartis Pharmaceuticals (1) · Syneos Health (1) · University Health Network, Toronto (1)
United States (4) · Switzerland (3) · Australia (1) · Canada (1) · Czechia (1) · India (1) · Italy (1) · New Zealand (1) · Portugal (1) · Spain (1)
Narinder Paul, FRCP C (1) · Peter Villiger, Prof (1) · Thomas Ciulla, MD (1)
PMID 27980877, PMID 32248659, PMID 34117737, PMID 35659282, PMID 37287970, PMID 38287611
2018 (2), 2023 (1)